AstraZeneca PLC (AZN)

AstraZeneca Gains FDA Nod for SAPHNELO At-Home Injection in Lupus Care

AstraZeneca plc (NASDAQ:AZN) has been granted approval by the U.S. Food and Drug Administration for a new self-injection format of SAPHNELO...

Koselugo est homologué au Canada pour le traitement des neurofibromes plexiformes chez les adultes atteints de neurofibromatose de type 1

Koselugo est homologué au Canada pour le traitement des neurofibromes plexiformes chez les adultes atteints...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

AstraZeneca Plans NYSE Move, Ending Nasdaq ADS Listing to Simplify US Share Trading

AstraZeneca (NASDAQ:AZN) has announced it will shift its US listing from Nasdaq to the New York Stock Exchange, delisting its American Depositary...

Walmart Shares Jump After Confirmation of Nasdaq-100 Index Inclusion

Walmart (NYSE:WMT) shares climbed about 3.6% on Monday morning after the retail giant was named as a new constituent of the Nasdaq-100 Index...

Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit

Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030 AstraZeneca has named...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer

Tenth Breakthrough Therapy Designation for AstraZeneca and Daiichi Sankyo’s ENHERTU with the latest based on DESTINY-Breast05 Phase III trial...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer

Based on DESTINY-Breast09 Phase III trial results that showed AstraZeneca and Daiichi Sankyo’s ENHERTU in combination with pertuzumab reduced the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]